Irvine-based Allergan Inc. on Monday said it received approvals from antitrust authorities in Germany and Spain for its buy of Santa Barbara’s Inamed Corp.
The antitrust clearances in the two countries are the only ones required outside the U.S.
Allergan is set to pay $3.2 billion in cash and stock for Inamed.
The companies also said they are working with the Federal Trade Commission to complete Inamed’s transfer of rights to Reloxin, its wrinkle reducer that’s seen as a rival to Allergan’s Botox, to Ireland’s Ipsen Pharmaceuticals Ltd.
Once that’s completed and the deal is approved in the U.S., Allergan can wrap up the buy.
“We continue to make good progress in our liaison with the U.S. regulatory authorities and anticipate receiving clearance from the Federal Trade Commission in the near future so we may consummate the acquisition,” said David Pyott, Allergan’s chief executive, in a statement.
